1887

Abstract

SUMMARY: The porA gene from Neisseria meningitidis was cloned into the pRSETA vector and recombinant class 1 outer-membrane protein expressed at high levels in Escherichia coli. The protein was readily purified by affinity chromatography on a Ni2+ matrix and used for immunization of mice with conventional AI(OH), adjuvant, with experimental adjuvants which have the potential for human use, and with liposomes. The resulting sera were analysed for the magnitude, subclass distribution and antigenic specificity of the immune response. In addition, surface plasmon resonance (SPR) was used to quantify antibody avidity by analysis of the kinetics of binding to native class 1 protein. Immunization withconventional and experimental adjuvants induced antibodies of low avidity that did not recognize native class 1 protein. In contrast, immunization with recombinant protein inliposomes induced antibodies of high avidity which recognized native class 1 protein, as measured by their ability t o label meningococcal cells in immunofluorescence assays and to inhibit the binding of a protective mAb. These properties were associated with the presence in sera of high levels of antibodies with the ability t o induce complement-mediated killing of meningococci. These data show that liposomes containing recombinant class 1 protein represent a potential basis of future vaccines, of defined composition, designed for the prevention of group B meningococcal infections.

Loading

Article metrics loading...

/content/journal/micro/10.1099/00221287-144-11-3027
1998-11-01
2021-08-04
Loading full text...

Full text loading...

/deliver/fulltext/micro/144/11/mic-144-11-3027.html?itemId=/content/journal/micro/10.1099/00221287-144-11-3027&mimeType=html&fmt=ahah

References

  1. Achtman M., Wall R.A., Bopp M., Kusecek B., Morelli G., Saken E., Hassanking M. 1991; Variation in class 5 protein expression by serogroup A meningococci during a meningitis epidemic.. J Infect Dis 164:375–382
    [Google Scholar]
  2. Barlow A.K., Heckels J.E., Clarke I.N. 1989; The class 1 outer membrane protein of Neisseria meningitidis: gene sequence and structural and immunological similarities to gonococcal porins.. Mol Microbiol 3:131–139
    [Google Scholar]
  3. Bjune G., Hoiby E.A., Gronnesby J.K. 14 other authors 1991; Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.. Lancet 338:1093–1096
    [Google Scholar]
  4. Boslego J., Garcia J., Cruz C. 11 other authors 1995; Efficacy, safety, and immunogenicity of a meningococcal group B (15-P1·3) outer-membrane protein vaccine in Iquique, Chile.. Vaccine 13:821–829
    [Google Scholar]
  5. Braun D.G., van Hoogevest P., Schumann G. 1995; Muramyl tripeptide-phosphatidylethanolamine: a muramyl dipeptide derivative with lipophilic properties.. In The Theory and Practical Application of Adjuvants pp. 213–238 Edited by Stewart-Tull D. E. S. Chichester: Wiley;
    [Google Scholar]
  6. Byars N.E., Allison A.C. 1987; Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.. Vaccine 5:223–228
    [Google Scholar]
  7. Carbonare S.B., Arslanian C., Silva M.M., Farhat C.K., Carneirosampaio M.S. 1995; The antimeningococcal vaccine VA-MENGOC-BC induced poor serum and salivary antibody- response in young Brazilian children.. Pediatr Infect Dis J 14:797–803
    [Google Scholar]
  8. Christodoulides M., McGuinness B.T., Heckels J.E. 1993; Immunisation with synthetic peptides containing epitopes of the class 1 outer membrane protein of Neisseria meningitidis-. production of bactericidal antibodies on immunisation with a cyclic peptide.. J Gen Microbiol 139:1729–1738
    [Google Scholar]
  9. Claassen I., Meylis J., van der Ley P. 9 other authors 1996; Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.. Vaccine 14:1001–1008
    [Google Scholar]
  10. Cryz S.J., Que J.U., Gluck R. 1996; A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans.. Vaccine 14:1381–1383
    [Google Scholar]
  11. Demoraes J.C., Perkins B.A., Camargo M.C.C. 9 other authors 1992; Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.. Lancet 340:1074–1078
    [Google Scholar]
  12. Finne J., Leinonen M., Makela P.H. 1983; Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis.. Lancet ii:355–357
    [Google Scholar]
  13. Frasch C.E., Robbins J.D. 1978; Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.. J Exp Med 147:629–644
    [Google Scholar]
  14. Frasch C.E., Zollinger W.D., Poolman J.T. 1985; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.. Rev Infect Dis 7:504–510
    [Google Scholar]
  15. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., Silverman C., Alving C.R. 1992; Liposomal malaria vaccine in humans - a safe and potent adjuvant strategy.. Proc Natl Acad Sci USA 89358–362
    [Google Scholar]
  16. Goldschneider I., Gotschlich E.C., Artenstein M.S. 1969; Human immunity to the meningococcus. I. The role of humoral antibodies.. J Exp Med 129:1307–1326
    [Google Scholar]
  17. Gregoriadis G. 1995; Liposomes as immunological adjuvants.. InThe Theory and Practical Application of Adjuvants pp. 145–169 Edited by Stewart-Tull D. E. S. Chichester: Wiley;
    [Google Scholar]
  18. Hermanson G.T., Mallia A.K., Smith P.K. 1992 Immobilised Affinity Ligand Techniques. London: Academic Press;
    [Google Scholar]
  19. Hoffman S.L., Edelman R., Bryan J.P. 13 other authors 1994; Safety, immunogenicity and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell-wall skeleton of mycobacteria, and squalane as adjuvant.. Am J Trop Med Hyg 51:603–612
    [Google Scholar]
  20. Hunter R., Olsen M., Buynitzky S. 1991; Adjuvant activity of nonionic block copolymers. 4. Effect of molecular weight and formulation on titer and isotype of antibody.. Vaccine 9:250–256
    [Google Scholar]
  21. Idanpaan-Heikkila I., Hoiby E.A., Chattopadhyay P., Airak-sinen U., Michaelsen T.M., Wedege E. 1995; Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease.. J Med Microbiol 43:335–343
    [Google Scholar]
  22. Jiskoot W., Teerlink T., Van Hoof M.M.M., Bartels K., Kanhai V., Crommelin D.J., Beuvery E.C. 1986; Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes.. Infect Immun 54:333–338
    [Google Scholar]
  23. Jonsson U., Fagerstam L., Ivarsson B. 13 other authors 1991; Real-time biospecific interaction analysis using surface-plasmon resonance and a sensor chip technology.. Biotechniques 11:620–627
    [Google Scholar]
  24. Karlsson R., Michaelsson A., Mattsson L. 1991; Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system.. J Immunol Methods 145:229–240
    [Google Scholar]
  25. van der Ley P., Heckels J.E., Virji M., Hoogerhout P., Poolman J.T. 1991; Topology of outer membrane porins in pathogenic Neisseria spp.. Infect Immun 59:2963–2971
    [Google Scholar]
  26. van der Ley P., van der Biezen J., Poolman J.T. 1995; Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine.. Vaccine 13:401–407
    [Google Scholar]
  27. McGuinness B.T., Lambden P.R., Heckels J.E. 1993; Class 1 outer membrane protein of Neisseria meningitidis-, epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology.. Mol Microbiol 7:505–514
    [Google Scholar]
  28. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E.A., Vieira V.S.D., Sato H., Brito G.S., Moraes J.C., Frasch C.E. 1994; Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.. Infect Immun 62:4419–4424
    [Google Scholar]
  29. Muttilainen S., Butcher S. J., Runeberg K., Nurminen M., Idanpaan-Heikkila I., Wahlstrom E., Sarvas M. 1995a; Heterologous production of the PI porin of Neisseria meningitidis in Bacillus subtilis: the effect of an N-terminal extension on the presentation of native-like epitopes.. Microb Pathog 18:365–371
    [Google Scholar]
  30. Muttilainen S., Butcher S. J., Runeberg K., Nurminen M., Idanpaan-Heikkila I., Wahlstrom E., Sarvas M. 1995b; The Neisseria meningitidis outer membrane protein PI produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native PI epitopes.. Microb Pathog 18:423–436
    [Google Scholar]
  31. Nurminen M., Butcher S., Idanpaan-Heikkila I., Wahlstrom E., Muttilainen S., Runeberg-Nyman K., Sarvas M., Makela P.H. 1992; The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity.. Mol Microbiol 6:2499–2506
    [Google Scholar]
  32. Peeters C.C.A.M., Rumke H.C., Sundermann L.C., van der Voort E.M.R., Meulenbelt J., Schuller M., Kuipers A.J., van der Ley P., Poolman J.T. 1996; Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine.. Vaccine 14:1009–1015
    [Google Scholar]
  33. Perkins B.A., Jonsdottir K., Briem H. 16 other authors 1998; Immunogenicity of two efficacious outer membrane protein- based serogroup B meningococcal vaccines among young adults in Iceland.. J Infect Dis 177:683–691
    [Google Scholar]
  34. Quan W.D.Y., Dean G.E., Spears L., Spears C.P., Groshen S., Merritt J.A., Mitchell M.S. 1997; Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus Saf-M.. J Clin Oncol 15:2103–2110
    [Google Scholar]
  35. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., Ronnild E., Bjune G., Nokleby H. 1995; Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.. Infect Immun 63:4642–4652
    [Google Scholar]
  36. Rudbach J.A., Johnson D.A., Urlich J.T. 1995; Ribi adjuvants: chemistry, biology and utility in vaccines for human and veterinary medicine.. In The Theory and Practical Application of Adjuvants pp. 287–314 Edited by Stewart-Tull D. E. S. Chichester: Wiley;
    [Google Scholar]
  37. Schultz N., Oratz R., Chen D.L., Zeleniuchjacquotte A., Abeles G., Bystryn J.C. 1995; Effect of Detox as an adjuvant for melanoma vaccine.. Vaccine 13:503–508
    [Google Scholar]
  38. Tinsley C.R., Heckels J.E. 1986; Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection.. J Gen Microbiol 132:2483–2490
    [Google Scholar]
  39. Tsai C.M., Frasch C.E., Mocca L.F. 1981; Five structural classes of major outer-membrane proteins in Neisseria meningitidis.. J Bacteriol 146:69–78
    [Google Scholar]
  40. Van Cott T.C., Bethke F.R., Polonis V.R., Gorny M.K., Zollapazner S., Redfield R.R., Birx D.L. 1994; Dissociation rate of antibody-gpl20 binding interactions is predictive of V3- mediated neutralization of HIV-1.. J Immunol 153:449–459
    [Google Scholar]
  41. Verma J.N., Rao M., Amselem S., Krzych U., Alving C.R., Green S.J., Wassef N.M. 1992; Adjuvant effects of liposomes containing Lipid A - enhancement of liposomal antigen presentation and recruitment of macrophages.. Infect Immun 60:2438–2444
    [Google Scholar]
  42. van der Voort E.R., van der Ley P., van der Biezen J., George S., Tunnela O., van Dijken H., Kuipers B., Poolman J. 1996; Specificity of human bactericidal antibodies against PorA Pl.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.. Infect Immun 64:2745–2751
    [Google Scholar]
  43. Ward S.J., Scopes D.A., Christodoulides M., Clarke I.N., Heckels J.E. 1996; Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response.. Microb Pathog 21:499–512
    [Google Scholar]
  44. Wedege E., Froholm L.O. 1986; Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting.. Infect Immun 51:571–578
    [Google Scholar]
  45. Wetzler L.M., Blake M.S., Gotschlich E.C. 1988; Characterization and specificity of antibodies to protein I of Neisseria gonorrhoeae produced by injection with various protein I- adjuvant preparations.. J Exp Med 168:1883–1897
    [Google Scholar]
  46. White D.A., Barlow A.K., Clarke I.N., Heckels J.E. 1990; Stable expression of meningococcal class 1 protein in an antigenically reactive form in outer membranes of Escherichia coli.. Mol Microbiol 4:769–776
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/00221287-144-11-3027
Loading
/content/journal/micro/10.1099/00221287-144-11-3027
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error